HIV Treatment Research at the Whitman-Walker Institute
The mission of the ACTG Network is to cure HIV and reduce the burden of disease due to HIV infection and its complications and co-morbidities, including tuberculosis and viral hepatitis. Below are a few trials underway at the Whitman-Walker Institute.
The studies below are recruiting:
A5380 (Purge-C)
This study treats participants, with or without HIV, who are experiencing recent or acute diagnosis of hepatitis C. The study aims to test if a shorter course of treatment might be effective in curing HCV than the current 6 month regimen. This study is currently open to enrollment at the Whitman-Walker Health Clinical Research Site. You can reach out to [email protected] if you are interested in participating.
The studies below are currently in follow up only:
A5379 (BEe-HIVe)
This clinical trial tests various hepatitis B vaccines in people living with HIV to find efficacious dosing. A new vaccine, called HEPLISAV-B, has been approved that may provide a better response than what has currently been used. The researchers will study whether this vaccine will prove to be more effective than the current standard.